Topics

High-grade gliomas | Treatment | Targeted therapy | Bevacizumab

Home > Publications > Topics > High-grade gliomas > Treatment > Targeted therapy > Bevacizumab

Liao Y, Bai X, Cao Y, Zhang M.
Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: A retrospective clinical study.
J Clin Neurosci. 2024 Jan 25;120:196-203. doi: 10.1016/j.jocn.2024.01.018? PMID: 38277995. Observational study. ˍ

Bai X, Xing H, Feng M, Ma W, Wang S.
Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study.
Cancer Manag Res. 2024 Nov 16;16:1617-1626. doi: 10.2147/CMAR.S481289. PMID: 39575164. Observational study. ˍ

Henriksen OM, Maarup S, Hasselbalch B, Poulsen HS, Christensen IJ, Madsen K, Larsen VA, Lassen U, Law I.
Magnetic resonance imaging and o-(2-[¹⁸F]fluoroethyl)-l-tyrosine positron emission tomography for early response assessment of nivolumab and bevacizumab in patients with recurrent high-grade astrocytic glioma.
Neurooncol Adv. 2024 Oct 24;6(1):vdae178. doi: 10.1093/noajnl/vdae178. PMID: 39659835. Interventional study. ˍ

Lim S, Clarke NH, Maloney SL, Sener UT, Caron SJ, Kizilbash SH, Campian JL, Neth BJ, Carabenciov ID, Uhm J, Ruff MW.
Bevacizumab exerts dose-dependent risk for intracranial hemorrhage in patients with malignant gliomas.
J Neurooncol. 2025 Jan 2. doi: 10.1007/s11060-024-04916-8. PMID: 39747716. Observational study˰ ˍ

Sahebjam S, Raval RR, Forsyth PA, Enderling H, Tran ND, Arrington JA, Macaulay R, Perlow HK, Palmer JD, Ghose J, Rajappa P, Giglio P, Li Z, Etame AB, Mokhtari S, Cruz-Chamorro RJ, Bhandari M, Thapa R, Robinson TJ, Chen DT, Yu HM.
Phase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomas.
Neurooncol Adv. 2025 Feb 8;7(1):vdaf033. doi: 10.1093/noajnl/vdaf033. PMID: 40134851. Interventional study. ˍ